Clinical Trials Logo
  1. Home
  2. Atrial Flutter
  3. NCT00491010
  4. Details
NCT00491010 Clinical Trial

Maximum Targeted Ablation of Atrial Flutter

Atrial Flutter Clinical Trial

Official title:
Maximum Targeted Ablation of Atrial Flutter

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00491010
Other study ID # R-06-153
Secondary ID 12266
Status Recruiting
Phase Phase 4
First received June 21, 2007
Last updated June 21, 2007
Start date July 2006
Est. completion date February 2008

Study information
Verified date June 2007
Source Lawson Health Research Institute
Contact Allan Skanes, MD
Phone 519-685-8500
Email askanes@uwo.ca
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Patients undergoing atrial flutter ablation will be randomized to either the standard ablation approach or voltage targeted approach. Patients will be followed for one year to assess outcome of the ablation technique

Recruitment information / eligibility
Status Recruiting
Enrollment 0
Est. completion date February 2008
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients undergoing TV-IVC isthmus ablatin for atrial flutter

Exclusion Criteria:

- atypical atrial flutter

- <18 years old any atrial surgery or pacemaker refusal to participate

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Procedure:
• radiofrequency catheter ablation

Locations
Country Name City State
Canada London Health Sciences Center London Ontario

Sponsors (1)
Lead Sponsor Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

See also
  Status Clinical Trial Phase
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Terminated NCT02317029 - Comparison of Oxygen Interventions and Defibrillator Efficiency N/A
Recruiting NCT01563848 - Cryoablation in Patients With Atrial Flutter Phase 2
Completed NCT01229254 - Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Phase 2
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Completed NCT00232232 - Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT05468281 - RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
Completed NCT03627143 - Decreasing Hospital Admissions From the ED for AAFF N/A
Completed NCT02917538 - A Randomized Trial of Contact Force in Atrial Flutter Ablation N/A
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting NCT05755074 - Ablation of Typical Right Atrial Flutter N/A
Recruiting NCT05883631 - RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. N/A
Recruiting NCT03272620 - Atrial Fibrillation at the Viennese University Emergency Department N/A
Completed NCT02810938 - MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
Recruiting NCT02591875 - Atrial Flutter Ablation in a Real World Population N/A
Completed NCT01914497 - Dipole Density Mapping of Typical Atrial Flutter N/A
Completed NCT02268799 - High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter N/A
Active, not recruiting NCT01976507 - Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Phase 4